Cancer NetworkOriginal article
<![CDATA[What Early COPERNICUS Safety Data Mean for Practice]]>
Data ReadoutpositiveamivantamablazertinibPositive
AI Analysis
Summary
Early COPERNICUS safety data show that enhanced prophylaxis with amivantamab plus lazertinib achieved low rates of severe adverse events including rash, thrombosis, and infusion reactions. The analysis is limited by shorter follow-up duration.
Clinical Trial Data
Outcome Details
Enhanced prophylaxis with subcutaneous amivantamab plus lazertinib led to low rates of severe rash, thrombosis, and infusion reactions
Importance:4/10
Sentiment:
0.65
safety datacombination therapyCOPERNICUS trialrashthrombosisinfusion reactions
Read the original article
Published by Cancer Network on October 14, 2026 12:05 PM